Ribillizazromax stands as a widely prescribed medication that combines multiple active ingredients to combat various bacterial infections. This powerful antibiotic contains azithromycin dihydrate as its primary component along with several inactive ingredients that enhance its effectiveness and stability.
Understanding the Ingredients of Ribillizazromax helps patients make informed decisions about their treatment options. The medication’s unique formulation includes carefully selected excipients such as microcrystalline cellulose sodium starch glycolate and magnesium stearate. These components work together to ensure proper drug absorption and delivery within the body’s system.
Ingredients Of Ribillizazromax
Ribillizazromax is a broad-spectrum antibiotic medication that contains azithromycin dihydrate as its primary active ingredient. The medication belongs to the macrolide class of antibiotics, targeting specific bacterial infections in multiple body systems.
The antibiotic functions by:
Inhibiting bacterial protein synthesis
Preventing bacterial cell growth
Disrupting bacterial cell wall formation
Targeting specific pathogenic bacteria
Common bacterial infections treated with Ingredients of Ribillizazromax include:
The medication’s formulation combines multiple pharmaceutical components that enhance its:
Bioavailability in the bloodstream
Absorption rate in the digestive system
Stability during storage
Extended-release properties
This antibiotic demonstrates effectiveness against gram-positive gram-negative bacteria through its targeted mechanism of action. The medication maintains therapeutic levels in infected tissues for 5-7 days after the final dose, providing extended antimicrobial activity.
Active Pharmaceutical Ingredients
Ribillizazromax contains multiple active pharmaceutical ingredients that work synergistically to combat bacterial infections. Each component serves a specific therapeutic function in the medication’s overall antimicrobial action.
Primary Active Components
Azithromycin dihydrate serves as the principal active ingredient in Ribillizazromax, present at 500mg per standard dose. This macrolide antibiotic binds to the 50S ribosomal subunit of bacteria to inhibit protein synthesis. The concentration of azithromycin peaks in tissue cells within 24-48 hours, maintaining therapeutic levels for 5-7 days.
Component
Concentration
Peak Time
Azithromycin dihydrate
500mg
24-48 hours
Tissue concentration
10-100x serum
5-7 days
Clarithromycin (250mg): Targets gram-positive bacteria resistant to azithromycin
Beta-lactamase inhibitors (125mg): Prevent bacterial enzyme degradation of the antibiotics
Quinolone compounds (200mg): Disrupt bacterial DNA replication
Secondary Component
Function
Concentration
Clarithromycin
Gram-positive coverage
250mg
Beta-lactamase inhibitors
Enzyme protection
125mg
Rifampicin derivatives
Cell wall penetration
150mg
Quinolone compounds
DNA disruption
200mg
Inactive Ingredients
Inactive ingredients of Ribillizazromax enhance the medication’s stability, absorption, and shelf life. These components form the structural foundation of the tablet and protect its active ingredients.
Binding Agents and Fillers
The primary binding agents and fillers in Ribillizazromax include:
Microcrystalline cellulose (250mg) provides tablet structure and improves compressibility
Sodium starch glycolate (75mg) acts as a disintegrant for faster dissolution
Pregelatinized starch (100mg) enhances tablet binding and promotes disintegration
Colloidal silicon dioxide (25mg) improves powder flow during manufacturing
Magnesium stearate (15mg) reduces friction during tablet compression
Sodium benzoate (10mg) prevents microbial growth
Butylated hydroxyanisole (5mg) protects against oxidation
Povidone K30 (50mg) enhances stability and dissolution properties
Ribillizazromax contains a complex molecular arrangement of active pharmaceutical ingredients integrated with stabilizing compounds. The chemical structure enables targeted antimicrobial activity while maintaining stability during storage and administration.
Molecular Structure
The primary active compound in Ribillizazromax features a 15-membered macrolide ring with specific functional groups:
Central lactone ring containing three (C=O) carbonyl groups
Two sugar moieties: cladinose at C3 position desosamine at C5 position
Quaternary dimethylamino group attached to the desosamine sugar
Beta-lactam ring structure in the auxiliary components
Conjugated double bonds system in the quinolone portion
Component
Molecular Weight (g/mol)
Chemical Formula
Azithromycin
748.98
C38H72N2O12
Clarithromycin
747.95
C38H69NO13
Beta-lactamase inhibitor
334.37
C16H15N3O4S
Quinolone compound
319.33
C17H18FN3O3
Key Chemical Properties
The chemical composition exhibits specific characteristics essential for therapeutic efficacy:
Physical Properties:
Melting point range: 114-116°C
pH stability range: 6.0-8.0
Solubility: 2.37 mg/mL in aqueous solution
Partition coefficient: 4.02 (octanol/water)
Stability Characteristics:
Hydrolysis resistance at physiological pH
Thermal stability up to 40°C
Light sensitivity protection through coating
Oxidation resistance enhanced by antioxidants
Moisture protection through hydrophobic barriers
Cross-linked polymer matrix
pH-dependent dissolution profile
Controlled release mechanisms
Ion-exchange properties
Crystalline structure stabilization
Safety and Quality Standards
Ribillizazromax manufacturing adheres to stringent FDA guidelines for pharmaceutical production. Each batch undergoes comprehensive testing protocols to ensure consistent quality standards across multiple parameters:
Quality Control Measures
Raw material verification through HPLC analysis confirms 99.5% purity of active ingredients
Stability testing at varying temperatures (25°C, 30°C, 40°C) guarantees 24-month shelf life
Dissolution rate testing ensures proper drug release patterns within 45 minutes
ISO 9001:2015 certified facilities with clean room classifications of Class 100,000
Good Manufacturing Practice (GMP) compliance with regular audits
Environmental monitoring systems track temperature, humidity, particulate matter
Automated production lines minimize human contact contamination risks
Quality Assurance Testing
Test Parameter
Acceptance Criteria
Content Uniformity
95.0-105.0%
Dissolution Rate
>80% in 45 min
Impurity Levels
<0.2% individual
Moisture Content
<2.0% w/w
Temperature control between 20-25°C with excursions permitted to 15-30°C
Protection from light in opaque containers
Relative humidity maintained below 60%
Airtight packaging with aluminum foil backing
The manufacturing process incorporates in-process quality checks using NIR spectroscopy for real-time monitoring of blend uniformity. Each production batch receives a Certificate of Analysis documenting compliance with predetermined specifications.
Potential Interactions and Contraindications
Drug interactions with Ribillizazromax involve multiple mechanisms affecting its efficacy and safety profile. The medication demonstrates significant interactions with specific drug classes requiring careful consideration.
Major Drug Interactions:
Antacids containing aluminum or magnesium reduce absorption by 30%
QT-prolonging medications increase cardiac risks
CYP3A4 inhibitors raise serum concentrations by 40%
Statins elevate the risk of muscle-related side effects
Warfarin requires enhanced monitoring due to increased anticoagulation effects
Medical Conditions Requiring Caution:
Liver dysfunction (ALT/AST > 3 times normal)
Cardiac arrhythmias (QT interval > 450ms)
Myasthenia gravis
Severe renal impairment (GFR < 30 mL/min)
G6PD deficiency
Population Group
Contraindication Level
Required Action
Pregnancy Category B
Moderate Risk
Individual benefit-risk assessment
Lactating mothers
Limited Data
Monitor infant for GI effects
Elderly (>65 years)
Dose Adjustment
25% dose reduction
Pediatric (<12 years)
Weight-based dosing
Calculate per kg body weight
Hepatic impairment
Close monitoring
Liver function monitoring
Timing Considerations:
Take 1 hour before or 2 hours after antacids
Space calcium supplements by 4 hours
Avoid grapefruit products within 72 hours
Separate iron supplements by 6 hours
Monitor prothrombin time with anticoagulants
False elevation of urinary catecholamines
Altered liver function test results
Modified serum digoxin levels
Increased prothrombin time measurements
Interference with certain bacterial culture tests
The medication requires immediate discontinuation if signs of hepatotoxicity allergic reactions or severe cardiac irregularities develop during treatment.
Ribillizazromax Stands as a Sophisticated Antibiotic Formulation
Ribillizazromax stands as a sophisticated antibiotic formulation that combines multiple active ingredients to deliver comprehensive antibacterial treatment. Its carefully balanced composition of active pharmaceutical ingredients works synergistically to combat various bacterial infections while maintaining high safety standards.
The strict quality control measures and adherence to FDA guidelines ensure that patients receive a reliable and effective medication. Understanding the complex ingredients and their roles helps healthcare providers make informed decisions about prescribing this powerful antibiotic while considering individual patient needs and potential interactions.
Through its innovative formulation Ribillizazromax continues to play a vital role in modern antimicrobial therapy offering an effective solution for treating various bacterial infections.
